Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

Patrick J. Perik; Maarten Alexander de Korte; Dirk J. van Veldhuisen; Jourik A. Gietema; Dirk T. Sleijfer; Elisabeth G. E. de Vries

doi:10.1586/14737140.7-12.1763

Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

Patrick J. Perik^*, Maarten Alexander de Korte, Dirk J. van Veldhuisen, Jourik A. Gietema, Dirk T. Sleijfer, Elisabeth G. E. de Vries

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

31 Citations (Scopus)

Abstract

The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.

Original language	English
Pages (from-to)	1763-1771
Number of pages	9
Journal	Expert review of anticancer therapy
Volume	7
Issue number	12
DOIs	https://doi.org/10.1586/14737140.7-12.1763
Publication status	Published - Dec-2007

Keywords

breast cancer
cardiotoxicity
HER2
trastuzumab
CONVERTING-ENZYME-INHIBITOR
CONGESTIVE-HEART-FAILURE
HIGH-DOSE CHEMOTHERAPY
PHASE-II TRIAL
ADJUVANT CHEMOTHERAPY
DILATED CARDIOMYOPATHY
CARDIAC DYSFUNCTION
VENTRICULAR MYOCYTES
MONOCLONAL-ANTIBODY
CLINICAL-PRACTICE

Access to Document

10.1586/14737140.7-12.1763

Handle.net

Persistent link

Cite this

@article{89eb72794882411cbbb05d4bdc9bd756,

title = "Cardiotoxicity associated with the use of trastuzumab in breast cancer patients",

abstract = "The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.",

keywords = "breast cancer, cardiotoxicity, HER2, trastuzumab, CONVERTING-ENZYME-INHIBITOR, CONGESTIVE-HEART-FAILURE, HIGH-DOSE CHEMOTHERAPY, PHASE-II TRIAL, ADJUVANT CHEMOTHERAPY, DILATED CARDIOMYOPATHY, CARDIAC DYSFUNCTION, VENTRICULAR MYOCYTES, MONOCLONAL-ANTIBODY, CLINICAL-PRACTICE",

author = "Perik, {Patrick J.} and {de Korte}, {Maarten Alexander} and {van Veldhuisen}, {Dirk J.} and Gietema, {Jourik A.} and Sleijfer, {Dirk T.} and {de Vries}, {Elisabeth G. E.}",

year = "2007",

month = dec,

doi = "10.1586/14737140.7-12.1763",

language = "English",

volume = "7",

pages = "1763--1771",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Taylor & Francis Group",

number = "12",

}

TY - JOUR

T1 - Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

AU - Perik, Patrick J.

AU - de Korte, Maarten Alexander

AU - van Veldhuisen, Dirk J.

AU - Gietema, Jourik A.

AU - Sleijfer, Dirk T.

AU - de Vries, Elisabeth G. E.

PY - 2007/12

Y1 - 2007/12

N2 - The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.

AB - The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.

KW - breast cancer

KW - cardiotoxicity

KW - HER2

KW - trastuzumab

KW - CONVERTING-ENZYME-INHIBITOR

KW - CONGESTIVE-HEART-FAILURE

KW - HIGH-DOSE CHEMOTHERAPY

KW - PHASE-II TRIAL

KW - ADJUVANT CHEMOTHERAPY

KW - DILATED CARDIOMYOPATHY

KW - CARDIAC DYSFUNCTION

KW - VENTRICULAR MYOCYTES

KW - MONOCLONAL-ANTIBODY

KW - CLINICAL-PRACTICE

U2 - 10.1586/14737140.7-12.1763

DO - 10.1586/14737140.7-12.1763

M3 - Review article

SN - 1473-7140

VL - 7

SP - 1763

EP - 1771

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 12

ER -

Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this